At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 160 enrolled
Drug / intervention
Bupivacaine 20mL 0.5% +2 moredrug
Likely dose
Bupivacaine 20mL 0.5%from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
In Brief
A Phase 4 clinical trial evaluating Bupivacaine 20mL 0.5%, Bupivacaine 20mL 0.25%, and 1 other intervention for Tendonitis. Completed, enrolled 160 participants across 1 site.
Detailed Summary
A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTendonitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJul 2021
Primary CompletionNov 2023
Study CompletionNov 2023
TodayJul 2026
First PostedApr 30, 2021
Enrollment StartJul 14, 2021
Primary CompletionNov 8, 2023
Study CompletionNov 11, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.2 years ago
Interventions
Bupivacaine 20mL 0.5%drug
Interscalene nerve block with 20 mL 0.5% bupivacaine.
Bupivacaine 20mL 0.25%drug
Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
Bupivacaine up to 15mL 0.25%drug
Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.